about
Overview and management of cardiac adverse events associated with tyrosine kinase inhibitorsManagement of chemotherapy induced cardiomyopathy.Cardio-oncology: a new medical issue.Differential cardiotoxic/cardioprotective effects of beta-adrenergic receptor subtypes in myocytes and fibroblasts in doxorubicin cardiomyopathy.Utilizing cardiac biomarkers to detect and prevent chemotherapy-induced cardiomyopathy.Cardiomyopathy associated with cancer therapy.
P2860
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Beta-blockade in adriamycin-induced cardiomyopathy.
@ast
Beta-blockade in adriamycin-induced cardiomyopathy.
@en
type
label
Beta-blockade in adriamycin-induced cardiomyopathy.
@ast
Beta-blockade in adriamycin-induced cardiomyopathy.
@en
prefLabel
Beta-blockade in adriamycin-induced cardiomyopathy.
@ast
Beta-blockade in adriamycin-induced cardiomyopathy.
@en
P2093
P1476
Beta-blockade in adriamycin-induced cardiomyopathy.
@en
P2093
P304
P577
2000-06-01T00:00:00Z